Featured Research

from universities, journals, and other organizations

Combining Radiation Modalities Increases Prostate Cancer Cure Rates

Date:
August 4, 2004
Source:
Mount Sinai Hospital / Mount Sinai School Of Medicine
Summary:
High-risk prostate cancer patients who undergo a combination of hormonal therapy, radioactive seed implant (also called brachytherapy) and external beam radiation therapy are shown to have an increased chance of cancer cure, according to a new study by researchers at Mount Sinai School of Medicine.

High-risk prostate cancer patients who undergo a combination of hormonal therapy, radioactive seed implant (also called brachytherapy) and external beam radiation therapy are shown to have an increased chance of cancer cure, according to a new study by researchers at Mount Sinai School of Medicine published in the August 1, 2004, issue of the International Journal of Radiation Oncology*Biology*Physics.

Historically, high-risk prostate cancer has been a therapeutic challenge for physicians, despite their efforts to cure patients by aggressively treating them with either surgery, brachytherapy or external beam radiation. Previous studies have shown the 5-year freedom from recurrence rates for high-risk patients treated with just one of these treatments to be between 0 and 50 percent, with up to half of these failures occurring where the original tumor was found.

To see if combining therapies would decrease recurrence rates for men with high-risk prostate cancer, 132 patients with high Gleason scores, high prostate-specific antigen (PSA) scores or who were at an advanced clinical stage of prostate cancer were studied. A three-pronged approach that included brachytherapy, external beam radiation therapy and hormonal therapy produced an 86 percent rate of freedom from recurrence after five years. In addition, 47 of the original 132 patients in the study had a prostate biopsy performed two years after the end of treatment and 100 percent of them showed no evidence of the cancer recurring.

"This is a very exciting study because it shows that this new approach of combining brachytherapy, external beam irradiation and hormonal therapy to cure prostate cancer can be very effective for men with aggressive forms of the disease," said Richard G. Stock, M.D., lead author of the study and Chairman of the Department of Radiation Oncology at Mount Sinai School of Medicine. "The data also supports the theory that enhanced local control can improve overall disease control."


Story Source:

The above story is based on materials provided by Mount Sinai Hospital / Mount Sinai School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Mount Sinai Hospital / Mount Sinai School Of Medicine. "Combining Radiation Modalities Increases Prostate Cancer Cure Rates." ScienceDaily. ScienceDaily, 4 August 2004. <www.sciencedaily.com/releases/2004/08/040804085535.htm>.
Mount Sinai Hospital / Mount Sinai School Of Medicine. (2004, August 4). Combining Radiation Modalities Increases Prostate Cancer Cure Rates. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2004/08/040804085535.htm
Mount Sinai Hospital / Mount Sinai School Of Medicine. "Combining Radiation Modalities Increases Prostate Cancer Cure Rates." ScienceDaily. www.sciencedaily.com/releases/2004/08/040804085535.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins